Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
| ▸ | CCR3 | P51677 | 3/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | GPR6 | P46095 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26049997 | 0.97 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| SCHEMBL1409317 | 0.93 | SLC6A2 (0.69) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| SCHEMBL940415 | 0.87 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| SCHEMBL15575038 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| SCHEMBL15575035 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| Hydrochloric Acid SCHEMBL69675 | 0.85 | SLC6A2 (0.65) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| SCHEMBL3121581 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| SCHEMBL3158663 | 0.85 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3289104 | 0.83 | HRH3 (0.68) | SLC6A2SLC6A3SLC6A4HRH1CCR3 | |
| Hydrochloric Acid SCHEMBL4227255 | 0.82 | HRH3 (0.67) | SLC6A2SLC6A3SLC6A4HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-2506716-B1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | SLC6A2 1318/4885SLC6A3 788/4885SLC6A4 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.